This page was machine-translated from the Korean original and has not been reviewed by a person. Quoted source material is left in its original language and is not translated. Korean original
Materials
5-
Samsung SDI's one-line statement in the semi-annual report about "mass production in 27" was read in conjunction with a KAIST research paper — the paper, which the company funded in terms of materials and research expenses, contains remaining challenges. · Nature Communications azidoate paper review · Semi-annual report and fair disclosure comparison · KIPRIS patent sample · Sulfide national R&D
A KAIST research team measured how the material selected by the company for its solid-state battery, which replaces liquid electrolyte with solid, reacts to humidity inside the factory. We compared the paper with statements the company made in regulatory filings and the newsroom, and with records from the Korean Intellectual Property Office.
-
When a solid-state battery news appears, check which stage of the roadmap it refers to — how to count the five obstacles listed in the 2026 solid electrolyte roadmap paper and 51 patents of Toyota and Samsung SDI · 18 research funding from 12 countries · 47 EU projects · 847 national R&D projects for solid-state batteries
In a solid-state battery where the liquid electrolyte is replaced with a solid, the solid component is called a solid electrolyte. We checked the 12 national research grants and 51 Japanese published patent applications disclosed 18 months later, along with the roadmap paper written by 30 people who gathered to determine where the next 10 years will go.
-
Analysis instrument filing based on an Ophthalmology Science paper — Eyepoint, 2024-05-08 · Readout case C099
Eyepoint cited a paper published in Ophthalmology Science in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the paper in the order it was written and the scope it actually presented. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
-
Hospital & Medical Service Plans regulatory filing citing a New England Journal of Medicine paper — Molina Healthcare, 2016-02-11 · Readout case C003
Molina Healthcare cited a paper published in the New England Journal of Medicine in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
-
Hospital & Medical Service Plans regulatory filing citing a New England Journal of Medicine paper — Molina Healthcare, 2016-01-11 · Readout case C002
Molina Healthcare cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way the paper was written and the scope it actually demonstrated in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.